Market Overview

Genome Editing Biotech Company EdiGene Raises $15 Million in Series pre-B Financing


EdiGene Inc., which develops genome editing technologies into novel
therapeutics for a broad range of diseases and into creative solutions
to advance drug discovery, today announced the successful completion of
approximately $15 Million in a Series pre-B financing.

The financing is led by new investor Lilly Asia Ventures (LAV). New
investor Huagai Capital participated in this round. Series A lead
investor IDG Capital, Series A investor WI Harper Group and other
insiders also participated in this round.

"This investment will allow us to continue advancing our promising
portfolio of therapeutic programs based on gene-editing technologies,"
said Dr. Dong Wei, CEO of EdiGene, "In addition, we will continue to
further develop our proprietary High Throughput Genome Screening
platforms into a comprehensive solution for our partners in key areas
such as drug sensitivity, drug resistance and synthetic lethality."

"We are excited to invest in EdiGene," said Dr. Fei Chen, Managing
Partner of Lilly Asia Ventures, "Gene editing is bringing evolutional
breakthrough to drug discovery and potential clinical therapeutics, and
we are pleased to collaborate with EdiGene team and to support EdiGene's
growth in the global market."

"This new round of financing led by Lilly Asia Ventures with
participation of new and existing investors further validates the
progress we have made and the potential of our platforms," said Dr.
Wensheng Wei, founder of EdiGene. "Now we are well positioned to further
advance our pipeline and get one step closer to help patients with our
technologies. We look forward to working with Lilly Asia Ventures and
other investors for the years to come."

About EdiGene, Inc

EdiGene Inc is founded in 2015, and now headquartered in Beijing, with
operational subsidiaries in Guangzhou, China and Cambridge, USA. Our
mission is to translate the cutting-edge genome editing technologies
into novel therapeutics for genetic diseases and cancer, and into
creative solutions to advance drug discovery. We leverage our
proprietary platforms to develop gene-editing therapies for a wide range
of diseases, and to conduct high-throughput genome screening to enable
dissection of functional big data in biological contexts.

About Lilly Asia Ventures (LAV)

Founded in 2008 and headquartered in Shanghai, LAV is a leading VC firm
investing in the biomedical, pharmaceutical and medical
devices/diagnostics industries in China and US. LAV provides
early-to-growth-stage companies with wise capital, professional
expertise and valuable resources. LAV has offices in
northern California, Shanghai and Hong Kong.

View Comments and Join the Discussion!